NFPA
MCID: NNF007
MIFTS: 42

Non-Functioning Pituitary Adenoma (NFPA)

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Non-Functioning Pituitary Adenoma

MalaCards integrated aliases for Non-Functioning Pituitary Adenoma:

Name: Non-Functioning Pituitary Adenoma 58 17
Non-Functioning Pituitary Gland Neoplasm 71
Nfpa 58

Characteristics:

Orphanet epidemiological data:

58
non-functioning pituitary adenoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Finland),1-9/100000 (Sweden),6-9/10000 (Belgium),6-9/10000 (Switzerland),6-9/10000 (United Kingdom),6-9/10000 (Finland);

Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Non-Functioning Pituitary Adenoma

MalaCards based summary : Non-Functioning Pituitary Adenoma, also known as non-functioning pituitary gland neoplasm, is related to pituitary tumors and adenoma. An important gene associated with Non-Functioning Pituitary Adenoma is SST (Somatostatin), and among its related pathways/superpathways are Relaxin signaling pathway and Endochondral Ossification. The drugs Pasireotide and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain, and related phenotypes are hypotension and vomiting

Related Diseases for Non-Functioning Pituitary Adenoma

Diseases related to Non-Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 pituitary tumors 31.4 SST GH1
2 adenoma 31.4 SST MUC1 GH1
3 pituitary adenoma 31.3 SST GHR GH1
4 functioning pituitary adenoma 31.2 SST GHR GH1
5 hypopituitarism 30.9 GHR GH1
6 pituitary apoplexy 30.9 SST GH1
7 hyperprolactinemia 30.6 SST GH1
8 pituitary adenoma, prolactin-secreting 30.5 SST GH1
9 acromegaly 30.4 SST GHR GH1
10 pituitary hormone deficiency, combined, 2 30.3 GHR GH1
11 pituitary carcinoma 30.3 SST MUC1
12 pituitary gland disease 30.0 SST GHR GH1
13 hypothyroidism 29.8 SST GHR GH1
14 uremia 29.7 GHR GH1
15 insulin-like growth factor i 29.7 SST GHR GH1
16 hyperthyroidism 29.6 SST GH1
17 meningioma, radiation-induced 29.5 SST S100B MUC1
18 chordoma 29.3 S100B MUC1
19 hypogonadism 10.4
20 hypogonadotropism 10.4
21 diabetes insipidus 10.4
22 pituitary adenoma 4, acth-secreting 10.3
23 acth-secreting pituitary adenoma 10.3
24 headache 10.3
25 growth hormone deficiency 10.2
26 pituitary-dependent cushing's disease 10.2 SST GH1
27 vipoma 10.2 SST GH1
28 pituitary adenoma 1, multiple types 10.2 SST GH1
29 ectopic cushing syndrome 10.2 SST S100B
30 fibrous dysplasia 10.1 SST GH1
31 kearns-sayre syndrome 10.1
32 yemenite deaf-blind hypopigmentation syndrome 10.1
33 ptosis 10.1
34 inappropriate adh syndrome 10.1
35 chromophobe adenoma 10.1
36 aip-related familial isolated pituitary adenomas 10.1
37 hypoadrenalism 10.1
38 rare surgical neurologic disease 10.1
39 traumatic brain injury 10.1 S100B GH1
40 islet cell tumor 10.1 SST GH1
41 short bowel syndrome 10.1 SST GH1
42 subependymal giant cell astrocytoma 10.1 SST S100B
43 childhood brain stem glioma 10.1 SST MUC1
44 ganglioneuroma 10.1 SST S100B
45 dwarfism 10.1 GHR GH1
46 laron syndrome 10.1 GHR GH1
47 pancreatoblastoma 10.1 SST MUC1
48 intestinal pseudo-obstruction 10.0 SST S100B
49 duodenum disease 10.0 SST MUC1
50 duodenum cancer 10.0 SST MUC1

Graphical network of the top 20 diseases related to Non-Functioning Pituitary Adenoma:



Diseases related to Non-Functioning Pituitary Adenoma

Symptoms & Phenotypes for Non-Functioning Pituitary Adenoma

Human phenotypes related to Non-Functioning Pituitary Adenoma:

58 31 (show top 50) (show all 58)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
2 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
5 progressive visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000529
6 increased circulating gonadotropin level 58 31 frequent (33%) Frequent (79-30%) HP:0000837
7 hypogonadotrophic hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000044
8 easy fatigability 58 31 frequent (33%) Frequent (79-30%) HP:0003388
9 male hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000026
10 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
11 abnormality of the menstrual cycle 58 31 frequent (33%) Frequent (79-30%) HP:0000140
12 secondary growth hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008240
13 impotence 58 31 frequent (33%) Frequent (79-30%) HP:0000802
14 decreased fertility in females 58 31 frequent (33%) Frequent (79-30%) HP:0000868
15 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
16 decreased fertility in males 58 31 frequent (33%) Frequent (79-30%) HP:0012041
17 female hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000134
18 adrenocorticotropin deficient adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011735
19 adrenocorticotropic hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011748
20 decreased circulating acth level 58 31 frequent (33%) Frequent (79-30%) HP:0002920
21 increased intraabdominal fat 58 31 frequent (33%) Frequent (79-30%) HP:0008993
22 decreased female libido 58 31 frequent (33%) Frequent (79-30%) HP:0030018
23 abnormality of hair density 58 31 frequent (33%) Frequent (79-30%) HP:0011357
24 anemia of inadequate production 58 31 frequent (33%) Frequent (79-30%) HP:0010972
25 seizures 58 31 occasional (7.5%) Occasional (29-5%) HP:0001250
26 ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000508
27 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
28 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
29 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
30 panhypopituitarism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000871
31 increased serum testosterone level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030088
32 bitemporal hemianopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0030521
33 oculomotor nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012246
34 central diabetes insipidus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000863
35 cranial nerve vi palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0006897
36 sudden loss of visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001117
37 fourth cranial nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0007011
38 internal ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007942
39 macroorchidism, postpubertal 58 31 occasional (7.5%) Occasional (29-5%) HP:0002050
40 reduced circulating prolactin concentration 31 occasional (7.5%) HP:0008202
41 nausea and vomiting 58 Frequent (79-30%)
42 macroorchidism 58 Occasional (29-5%)
43 cranial nerve paralysis 58 Occasional (29-5%)
44 erectile abnormalities 58 Frequent (79-30%)
45 anterior hypopituitarism 58 Frequent (79-30%)
46 hemianopia 58 Occasional (29-5%)
47 hypogonadism 58 Frequent (79-30%)
48 diabetes insipidus 58 Occasional (29-5%)
49 growth hormone deficiency 58 Frequent (79-30%)
50 central adrenal insufficiency 58 Frequent (79-30%)

Drugs & Therapeutics for Non-Functioning Pituitary Adenoma

Drugs for Non-Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
2
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
3
Cabergoline Approved Phase 3 81409-90-7 54746
4
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
5
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
6 Garlic Approved, Nutraceutical Phase 3
7
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
8 Hormone Antagonists Phase 2, Phase 3
9 Hormones Phase 2, Phase 3
10 Neurotransmitter Agents Phase 3
11 Dopamine Agents Phase 3
12 Dopamine agonists Phase 3
13 Antiparkinson Agents Phase 3
14 Sympathomimetics Phase 2, Phase 3
15 Autonomic Agents Phase 2, Phase 3
16 Protective Agents Phase 2, Phase 3
17 Vitamins Phase 3
18 Trace Elements Phase 3
19 Nutrients Phase 3
20 Micronutrients Phase 3
21 Ubiquinone Phase 3
22 Gastrointestinal Agents Phase 3
23 Antineoplastic Agents, Hormonal Phase 3
24 Edotreotide Phase 3
25 Radiopharmaceuticals Phase 3
26
tannic acid Approved 1401-55-4
27
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
2 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH) Completed NCT00860847 Phase 3
4 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
5 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
6 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
7 Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) Unknown status NCT00852501
8 Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep Completed NCT01169155
9 Effects of Combined Diet & Exercise Intervention on Cardiovascular Risk Factors in Volunteer Firefighters & Non-Firefighters Recruiting NCT03344198
10 Development of a Cardiorespiratory Risk Surveillance Score Via Comparison of Body Composition Methods, Cardiorespiratory Fitness, and Obesity in Firefighters Recruiting NCT03585335
11 Multicentric Prospective Validation of the Zurich Pituitary Score Not yet recruiting NCT04076046
12 Emergency Egress and Information System for Persons With Vision Loss Terminated NCT00262509

Search NIH Clinical Center for Non-Functioning Pituitary Adenoma

Genetic Tests for Non-Functioning Pituitary Adenoma

Anatomical Context for Non-Functioning Pituitary Adenoma

MalaCards organs/tissues related to Non-Functioning Pituitary Adenoma:

40
Pituitary, Thyroid, Brain, Lung, Heart, T Cells, Bone

Publications for Non-Functioning Pituitary Adenoma

Articles related to Non-Functioning Pituitary Adenoma:

(show top 50) (show all 186)
# Title Authors PMID Year
1
Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma. 61
32015217 2020
2
Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma. 61
31907611 2020
3
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31896156 2020
4
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31931533 2020
5
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. 61
31796052 2019
6
Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas. 61
31776295 2019
7
Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma. 61
31601299 2019
8
Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature. 61
31406488 2019
9
Significance of Elevated HMGB1 Expression in Pituitary Apoplexy. 61
31366550 2019
10
Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. 61
31204511 2019
11
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. 61
30406929 2019
12
Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma. 61
31303851 2019
13
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. 61
31109334 2019
14
The burden of disease for pituitary patients. 61
31405752 2019
15
Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma. 61
30861564 2019
16
Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study. 61
30643415 2019
17
Intractable Rathke's cleft cyst hidden behind co-existing giant pituitary adenoma - Case report. 61
30610983 2019
18
A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. 61
30542712 2019
19
Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma. 61
30649793 2019
20
Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network. 61
30504132 2019
21
Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. 61
30590584 2018
22
FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study. 61
30206133 2018
23
Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and epithelial membrane antigen (EMA). 61
30431381 2018
24
Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement 61
30299891 2018
25
Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery. 61
29572634 2018
26
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma. 61
29910227 2018
27
Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. 61
30049813 2018
28
Data of phosphoproteomic analysis of non-functioning pituitary adenoma. 61
29900237 2018
29
Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? 61
29318507 2018
30
How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. 61
29302835 2018
31
Mortality in patients with non-functioning pituitary adenoma. 61
29344906 2018
32
Effects of active acromegaly on bone mRNA and microRNA expression patterns. 61
29374071 2018
33
Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq. 61
30026929 2018
34
Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia. 61
29660734 2018
35
Pituitary Carcinoma in a Patient with an SDHB Mutation. 61
28284009 2017
36
Amelanotic melanocytoma of the sella mimicking pituitary adenoma. 61
28853696 2017
37
In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. 61
28634279 2017
38
Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. 61
28596421 2017
39
Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas. 61
28759937 2017
40
Pituitary adenoma with adipose tissue: A new metaplastic variant. 61
28070930 2017
41
The impact on cognitive functions of patients with pituitary adenoma before and after surgery. 61
28478494 2017
42
Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015). 61
28389053 2017
43
Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. 61
28274953 2017
44
Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. 61
27743172 2017
45
Clinical characteristics and risk factors for headache associated with non-functioning pituitary adenomas. 61
27154998 2017
46
Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. 61
27770012 2017
47
Is Positive Staining of Non-Functioning Pituitary Adenomas for Luteinizing Hormone Associated with a Poor Prognosis? 61
27593756 2017
48
All that glitters on PET is not cancer! 18F-deoxy-glucose avidity versus tumor biology: pituitary incidentaloma in a survivor of two previous unrelated malignancies. 61
28660992 2017
49
Relationship of each anterior pituitary hormone deficiency to the size of non-functioning pituitary adenoma in the hospitalized patients. 61
27534814 2016
50
Co-occurrence of Pituitary Adenoma with Suprasellar and Olfactory Groove Meningiomas. 61
27872697 2016

Variations for Non-Functioning Pituitary Adenoma

Expression for Non-Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Non-Functioning Pituitary Adenoma.

Pathways for Non-Functioning Pituitary Adenoma

Pathways related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.73 SST GHR GH1
2 10.97 GHR GH1
3
Show member pathways
10.24 GHR GH1

GO Terms for Non-Functioning Pituitary Adenoma

Cellular components related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 SST S100B MUC1 GHR GH1
2 neuronal cell body GO:0043025 9.43 SST S100B GHR
3 extracellular space GO:0005615 9.35 SST S100B MUC1 GHR GH1
4 growth hormone receptor complex GO:0070195 8.62 GHR GH1

Biological processes related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.4 GHR GH1
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.37 GHR GH1
3 response to glucocorticoid GO:0051384 9.32 S100B GHR
4 positive regulation of multicellular organism growth GO:0040018 9.26 GHR GH1
5 positive regulation of JAK-STAT cascade GO:0046427 9.16 GHR GH1
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.96 GHR GH1
7 growth hormone receptor signaling pathway GO:0060396 8.62 GHR GH1

Sources for Non-Functioning Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....